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1150-9 A Beta Chemokine (MCP-1)-Induced Antigen- 
Independent Cellular and Not s Humoral Immune 
Response Can Be Stimulated After Stent Percutaneous 
Trensluminal Coronary Angioplaety 
Emanuel V. Eoonomg~, Christos Pitsavos, Anastasia Katinioti, Konstantinos Tedolouris, 
Athanasios Trikas, Madna Toutouza, Chdstodoulos Stafandis, Pavlos Toutouzas, Dept. 
Cardiol., Uni~ Athens, Hippokration Hospital, Athens, Greece. 
Background : The beta chemokines MCP-1 and RANTES activate and attract mono- 
cytes/macrophages and T-lymphocytes and thus, they can both stimulate antigen-inde- 
pendent cellular immune response. Autoantibodies to vascular endothelial damage- 
related externalized phosphatidylserine (aPS) or to its preferential cover annexin V 
(aANX-V), both indicate stimulation of humoral immune respone. Aim of this study was to 
delineate if any type of immune respone can be stimulated after acute coronary endothe- 
lial damage (CED)-related stent-percutaneous transluminal coronary angioplasty (stent- 
PTCA). Methods : 40 patients (pts) with coronary artery disease (CAD) underwent a pri- 
mary successful, single-vessel, stent-PTCA. 20 CAD pts who underwent only coronary 
angiography (CA) and 20 healthy subjects (HS) served as controls. Peripheral blood was 
sampled at besaline before and 24 hours after PTCA or CA as well as 3 and 6 months 
after PTCA and was evaluated for plasma levels of MCP-1, RANTES, aPS and aANX-V. 
Results : At baseline, PTCA pts presented plasma levels of MCP-1 (460±62 pg/mL) and 
RANTES (25.8±2.5 ng/mL) both similar to the respective levels of CA pts (MCP-1 : 
449±87 pg/mL and RANTES : 24.2±3.1 ng/mL) but higher than the respective levels of 
HS (MCP-1 : 97±12 pg/mL, p=0.002 and RANTES : 10.1±2.6 ng/mL, p=0.0001). After 
PTCA, only MCP-1 levels attained a gradual increase at all the interval times assessed 
(24h after : 618±78 pg/mL, 3m after : 676±78 pg/mL, 6m after : 714 ±64 pg/mL, p<0.05 in 
all cases compared with the corresponding value of the previous interval assessing 
time). No other changes in MCP-1 and RANTES levels were noticed after PTCA or CA at 
all the interval times assessed, in comparison to the corresponding levels before the 
respective procedure. Both aPS and aANX-V were undetectable in plasma of all PTCA 
pts, CA pts and HS, at any time assessed. Conclusions : In CED-related CAD, MCP-1 
and RANTES can both stimulate antigen-independent cellular immune response. How- 
ever, in acute CED-related stent-PTCA, only MCP-1 can stimulate such a response. 
There is not conclusive evidence that CAD or stent.PTCA are associated in an important 
way to stimulation of any CED-relatad humoral immune respone. 
1150-10 Alphs-Melanocyte Stimulating Hormone Inhibits 
Porcine Vascular Smooth Muscle and Endothelial Cell 
Responses to Tumor Necrosis Factor-Alpha 
John W. Havcock, Sheila MacNeil, Cathy M. Holt, Nadim Malik, Department of 
Engineering Materials, University of Sheffield, Sheffield, United Kingdom, Unit of Cardiac 
Physiology, Manchester Universi~ Manchester, United Kingdom. 
Background: The long-term success of percutaneous coronary interventions (PCI) is lim- 
ited by restenosis due to neointima formation. Early inflammation, apoptosis and prolifer- 
ation at the site of injury play a role in neointima formation. AIpha-melanocyte stimulating 
hormone (alpha-MSH) can inhibit inflammation by blocking intracellulg.r pathways trig- 
gered by several inflammatory cytokines in cells expressing MSH receptors (MC-1). 
Alpha-MSH has previously been demonstrated to inhibit NF-kB transcription factor acti- 
vation by TNF-alpha. However, the in vitro and in vivo effects of alpha-MSH on vascular 
smooth muscle ceils (VSMC) and endothelial cells are not known. 
Methods: Immuno-labelling of cultured porcine VSMC and endothelial cells has identified 
positive MC-1 receptor surface expression. Stimulation with human or porcine TNF-alpha 
induced NF-kB/p65 activation in both VSMC and endothelial ceils. NF-kB/p65 activation 
was determined by digital immunofluorescent nuclear tracking. 
Results: Alpha-MSH (10-9M) significantly inhibited TNF-arpha stimulated activation of 
.NF-kB by 50% (± 9%) in VSM cells and 48% (±10%) in endothelial ceils. Preliminary in 
vivo data obtained from oversize angioprasty injury to porcine coronary adery following 
local or systemic alpha-MSH delivery revealed a reduction in inflammation at the injury 
site one hour post-angioplasty. 
Conclusions: Our data suggests that alpha-MSH has potential for preventing local inflam- 
mation following angioplasty by inhibiting the NF-kB/p65 pro-inflammatory signalling 
pathway. Alpha-MSH inhibition of stenosis following PCI in pig arteries is presently being 
investigated. 
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850-1 The Influence of Intravascular Ultrasound Guidance on 
In-Hospital Outcomes After Stent Implantation: Results 
From the Brazilian Society of  In tarvent iona l  Cardiology 
Registry - CENIC 
Amanda Souse. Alexandre Abizaid, Gary Mintz, Luiz A. Mattos, Cantideo Campos, 
Angela Paes, Jamil Saed, Costantino Costantini, Gilvan Dourado, Hello Figueira, 
Klauber Carneiro, Alcides Zago, Expedito Ribeiro, J. Eduardo Souse, on behalf of 
CENIC Participants, Brazilian Society of Interventional Cardiology - CENIC, Sao Pauio, 
Brazil, institute Dante Pazzanese of Cardiology, Sac Paulo, Brazil. 
Background: It remains unclear if the use of intravascular ultrasound (IVUS-G) has any 
influence on the in-hospital Outcome after stenting (ST). 
Methods: From 1997 to 2000 a prospective clinical survey was made in 133 Brazilian 
Hospitals. In these Institutions 41,821 patients (pts) were treated with ST and were 
grouped according to IVUS-G or not. Logistic regression analysis was used to identify the 
independent predictors of in-hospital complications (death, myocardial infarction or 
urgent bypass surgery). 
Results: 
IVUS-G No IVUS-G p 
Number of Patients 2,359 (5.6%) 39,462 (94.4%) 
Age (y) 59.7 ± 10.9 60.7 + 11.1 < 0.001 
Male (%) 70.4 69.9 0.585 
Diabetes (%) 16.5 17.1 0.488 
Unstable Angina (%) 24.0 21.1 0.001 
Angiographic Thrombus (%) 18.8 20.1 0.068 
Angiographic Calcium (%) 31.4 19.0 < 0.001 
Residual Stenosis (%) 8.3 ± 10.8 10.6 ± 11.6 < 0.001 
Procedural Success (%) 98.9 98.6 0.213 
In-hospital Death (%) 0.4 1.1 0.002 
In-hospital MI (%) 0.6 1.0 0.066 
In-hospital Death/MI (%) 0.9 1.8 0.001 
The independent predictors of in-hospital complications were: the use of IVUS-G (Odds 
Ratio 0.55; 95% CI 0.35 - 0.87; p = 0.0108), age (p < 0.001), thrombus (p < 0.001), % DS 
post ST (p < 0.001). 
Conclusions: In a large multicentar egistry of 41,821 pts in 133 centers, IVUS guidance 
was associated with: (1) lower residual stenosis, and (2) fewer in-hospital complications 
(including death and MI) despite increased patient and lesion complexity. 
10:45 a.m. 
850-2 Anglography Versus Intravascular Ultrasound-Directed 
Stent Placement: A Cost Analysis From AVID 
Robert J. Russo, Patricia D. Silva, The AVID Investigators, Scripps Clinic, La Jolla, 
California. 
Background: AVID (Angiography Vs. Intravascular ultrasound [IVUS]-Diracted stent 
placement) is a multicenter randomized trial to determine the effect of IVUS-directed stent 
placement on clinical outcome. Results include a 12-month target lesion revasculadzation 
(TLR) rate of 4.9% in the IVUS group and 10.8% in the angiography group when protocol 
violations are excluded (p=0.02). 
Methods: To determine the cost of IVUS- and angiography-diracted stent placement, 
resource utilization was assessed for both groups within 12 months. Acute procedural 
resource utilization included the cost of IVUS catheters, PTCA balloons, stents and proce- 
dure time related to IVUS-dirocted additional therapy. Post-procedure costs included in- 
hospital complications, as well as readmission for MI, repeat coronary angiography, and 
repeat PTCA or CABG for TLR within 12 months, Medicare hospital reimbursements for 
MI, unstable angina, coronary angiography, PTCA, and CABG were obtained for 10 clinical 
sites and adjusted using institution-specific cost-to-charge ratios. Medicare schedules were 
used for physician fee reimbursement rates. Costs were compared using a two-sample t- 
test. 
Results: At 24 centers 800 patients were randomized--394 to IVUS and 406 to angiogra- 
phy, The mean number of 15ram stents used was 1.5±0.9 in the IVUS and 1.4±0.7 in the 
angiography group (p=0.01). In the IVUS group, 42% required additional therapy to fulfill 
criteria; 29% for an underdilated stent. The mean acute procedural cost per patient in the 
IVUS group was $863 greater than the angiography group ($3528±1351 vs. $2645±1122; 
p<0.01 ), The mean pest-procedure cost per patient due to procedural complications, hospi- 
tal readmission, repeat angiography and PTCA/CABG for TLR was $1329±2939 in the 
IVUS and $1629±3219 in the angiography group (p=0.27). The 12-month cumulative cost 
was $4857±3240 in the IVUS group and $4274±3516 in the angiography group (p=0.05). 
Conclusions: IVUS-directed slant placement results in significantly lower 12-month TLR 
